Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
Recursion Pharmaceuticals director Christopher Gibson reported an insider trade involving the company’s Class A and Class B shares. On June 5, 2026, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock and sold those Class A shares at $3.62 per share.
The filing states this sale was made pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025, indicating it was pre-planned. After these transactions, Gibson held 923,735 shares of Class A Common Stock and 4,263,334 shares of Class B Common Stock directly, suggesting the 40,000-share sale represents only a small portion of his overall position.
Recursion Pharmaceuticals CEO and President Najat Khan reported an open-market sale of 23,588 shares of Class A Common Stock at a weighted average price of $3.5806 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025.
After this sale, Khan directly holds 2,175,796 shares, indicating she retains a substantial ownership stake in the company while taking limited liquidity through this planned transaction.
Najat Khan filed a Rule 144 notice to sell Common Stock of Recursion Pharmaceuticals. The filing lists intended sales dated 05/15/2026 of 18,422 shares and 7,788 shares described as Equity Compensation. The excerpt also reports a prior sale of 28,298 shares on 03/09/2026 for $94,662.47.
Christopher C. Gibson filed a Form 144 reporting a proposed sale of 40,000 Class A shares. The filing lists multiple sales of 40,000 Class A shares each during March–May 2026 with proceeds shown per trade.
Reported sales: 03/23/2026 $130,000; 04/07/2026 $124,000; 04/22/2026 $144,400; 05/07/2026 $134,800; 05/22/2026 $123,200.
RECURSION PHARMACEUTICALS director Namandje Bumpus sold shares in a pre-planned trade. On this Form 4, Bumpus reported an open-market sale of 4,386 shares of Class A common stock at an average price of $3.54 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After this transaction, Bumpus directly holds 43,171 shares of Recursion Pharmaceuticals, so the sale reflects only a portion of the director’s overall stake.
Recursion Pharmaceuticals director Blake Borgeson sold shares in a planned trade. On June 2, he executed an open-market sale of 30,000 shares of Class A Common Stock at $3.68 per share. After the sale, he directly holds 6,169,863 shares. The transaction was made under a Rule 10b5-1 trading plan adopted on August 31, 2025.
RXRX submitted a Form 144 notice describing proposed or reported sales of Class A shares. The filing lists multiple transactions by Blake C. Borgeson: 170,000 shares on 03/03/2026 for $588,200, 30,000 shares on 04/07/2026 for $93,000, and 30,000 shares on 05/05/2026 for $105,600. The excerpt also shows a 30,000-share allocation labeled as Founders Shares dated 09/19/2017 and an entry for Fidelity Brokerage Services LLC with 30,000 and $110,400.
RECURSION PHARMACEUTICALS director Christopher Gibson converted and sold shares in a planned set of transactions. On May 22, 2026, he converted 40,000 shares of Class B Common Stock into 40,000 shares of Class A Common Stock, then sold those 40,000 Class A shares in an open-market transaction at $3.08 per share. The filing notes the activity was carried out under a Rule 10b5-1 trading plan adopted on May 12, 2025, indicating the trades were pre-scheduled. After these moves, he directly holds 883,735 Class A shares and 4,303,334 Class B shares, with each Class B share convertible into one Class A share.
RXRX discloses a Form 144 notice showing proposed sales of Class A shares totaling 40,000 shares via Fidelity Brokerage Services LLC. The filing also lists recent open-market sales by Christopher C. Gibson on 03/23/2026, 04/07/2026, 04/22/2026, and 05/07/2026, each for 40,000 shares with aggregate transaction amounts shown in the record.